Volume 4, Issue 2, December 2020, Page: 63-71
Evolution of Susceptibilities of Helicobacter pylori Strains Circulating in Cameroon to Usual Antibiotics: A Three-year Study
Eyoum Bille Bertrant, Department of Biochemistry, Faculty of Science, University of Dschang, Dschang, Cameroon; Department of Diagnosis and Treatment Support, Laquintinie Hospital Douala, Douala, Cameroon
Tali Nguefak Lionel Danny, Department of Biochemistry, Faculty of Science, University of Dschang, Dschang, Cameroon
Fotso Chimi Serge, Department of Diagnosis and Treatment Support, Laquintinie Hospital Douala, Douala, Cameroon
Malongue Agnes, Department of Internal Medicine, General Hospital Douala, Douala, Cameroon; Department of Internal Medicine, Faculty of Medicine and pharmaceutical sciences, University of Douala, Douala, Cameroun
Ateba Mbassa Roger, Department of Diagnosis and Treatment Support, Laquintinie Hospital Douala, Douala, Cameroon
Kuiate Jules Roger, Department of Biochemistry, Faculty of Science, University of Dschang, Dschang, Cameroon
Kouitcheu Mabeku Laure Brigitte, Department of Biochemistry, Faculty of Science, University of Dschang, Dschang, Cameroon
Received: Oct. 9, 2020;       Accepted: Oct. 22, 2020;       Published: Nov. 19, 2020
DOI: 10.11648/j.ijg.20200402.17      View  21      Downloads  10
Abstract
This study was conducted to estimate the evolution of antimicrobial susceptibilities of H. pylori strains isolated in Cameroon from 2014 to 2016 in relation to sociodemographic factors and clinical outcomes. A total of 278 H. pylori strains were isolated from patients with gastroduodenal disorders and tested for their susceptibility to nine antibiotics using the disc diffusion method. With time, a significant decreased of resistance was observed against clarithromycin (31.11 to 3.20%, p<0.0001), erythromycin (66.69 to 9.6%, p<0.0001) and metronidazole (86.67 to 69.6%, p<0.0001). Resistance to tetracycline (0 to 2.4%) and doxycycline (0 to 1.6%) slightly increase with time. Resistance to amoxicillin (95.5 to 94.4%), ciprofloxacin (4.44 to 4%) and levofloxacin (0 to 0.8%) was relatively constant. No resistance was detected against rifampicin with the time. A significant decrease of resistance was detected against metronidazole / clarithromycin (22.22 to 1.6%, p<0.0001) and amoxicillin / clarithromycin (26.67 to 3.2%, p<0.0001). Among the tested isolates, 0.92 and 2.4% elicited triple resistance to metronidazole / tetracycline / amoxicillin in 2015 and 2016, and 0.8% quadruple resistance to metronidazole / tetracycline / clarithromycin / amoxicillin in 2016. Higher resistance rate was noticed as age increase and among female compared to men. Our data showed evolution in the antimicrobial susceptibilities of H pylori strains circulating in our milieu with time. This finding highlights the need of monitoring periodically H. pylori resistance profile to antibiotics in order to determine the adapted treatment for this infection.
Keywords
Helicobacter pylori, Antibiotics, Resistance Evolution, Cameroon
To cite this article
Eyoum Bille Bertrant, Tali Nguefak Lionel Danny, Fotso Chimi Serge, Malongue Agnes, Ateba Mbassa Roger, Kuiate Jules Roger, Kouitcheu Mabeku Laure Brigitte, Evolution of Susceptibilities of Helicobacter pylori Strains Circulating in Cameroon to Usual Antibiotics: A Three-year Study, International Journal of Gastroenterology. Vol. 4, No. 2, 2020, pp. 63-71. doi: 10.11648/j.ijg.20200402.17
Copyright
Copyright © 2020 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Warren JR, Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. The Lancet. 1983; 321: 1273-1275.
[2]
Conférence de Consensus. Maladie ulcéreuse et gastrite à l’heure de Helicobacter pylori. Conclusions et recommandations du jury. Gastroenterol Clin Biol. 1996; 20: S155-162.
[3]
Malfertheiner P, Megraud F, O’Morain C, Hungin APS, Jones R, Axon DY, et al. Current concepts in the management of Helicobacter pylori infection. The Maastricht 2000 Consensus Report. Aliment Pharmacol Ther. 2002; 16: 167-80.
[4]
Hunt R, Xiao S, Megraud F, Leon-Barua R, Bazzoli F, van der Merwe S, Coelho LV, et al. Helicobacter pylori in developing countries. World Gastroenterol Organ Global Guidelines. 2010; 1-15.
[5]
Gisbert JP, Molina-Infante J, Amador J, Bermejo F, Bujanda L, Calvet X, et al. IV Spanish Consensus Conference on Helicobacter pylori infection treatment. Gastroenterología y Hepatología (English Edition). 2016; 39: 697-721.
[6]
Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut. 2012.
[7]
De Francesco V, Giorgio F, Hassan C, Manes G, Vannella L, Panella C, et al. Worldwide H. Pylori antibiotic resistance: a systematic. J Gastrointestin Liver Dis. 2010; 19: 409-14.
[8]
Ghotaslou R, Leylabadlo HE, Asl YM. Prevalence of antibiotic resistance in Helicobacter pylori: a recent literature review. World J Methodol. 2015; 5: 164.
[9]
O'connor A, Lamarque D, Gisbert JP, O'morain C. Treatment of Helicobacter pylori infection. Helicobacter. 2017; 22: (S1).
[10]
Seck A. Maladie ulcéreuse gastroduodénale et Helicobacter pylori: Profil de sensibilité des souches de Hp isolées à Dakar. Thèse Pharm, Dakar p. 110. 2001.
[11]
Sherif M, Mohran Z, Fathy H, Rockabrand DM, Rozmajzl PJ, Frenck RW. Universal high-level primary metronidazole resistance in Helicobacter pylori isolated from children in Egypt. J Clin Microbiol. 2004; 42: 4832-34.
[12]
Chaabouni H, Bouzid H, Masmoudi A, Cheikh I, Fendri C, Ben Ammar A. Evaluation in vitro de la résistance primaire de Helicobacter pylori aux antibiotiques chez les ulcéreux duodénaux tunisiens. SNFGE. 2004.
[13]
Kouitcheu Mabeku LB, Eyoum Bille B, Tepap Zemnou C, Tali Nguefack LD, Leundji H. Broad spectrum resistance in Helicobacter pylori isolated from gastric biopsies of patients with dyspepsia in Cameroon and efflux-mediated multiresistance detection in MDR isolates. BMC Infectious Diseases. 2019; 19: 880.
[14]
Ndip RN, MalangeTakang AE, Ojongokpoko JE, et al. Helicobacter pylori isolates recovered from gastric biopsies of patients with gastro-duodenal pathologies in Cameroon: current status of antibiogram. Trop Med Int Health. 2008; 13: 848-854.
[15]
Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon ATR, Bazzoli F, et al. Management of Helicobacter pylori infection – the Maastricht IV/Florence Consensus Report. Gut. 2012; 61: 646-64.
[16]
Kouitcheu Mabeku LB, Noundjeu Ngamga ML, Leundji H. Potential risk factors and prevalence of Helicobacter pylori infection among adult patients with dyspepsia symptoms in Cameroon. BMC infectious diseases. 2018; 18: 278.
[17]
Comité de l’antibiogramme de la société Française de microbiologie [CASFM]. (2014). Recommandation 2014. p. 117. www.sfm-microbiologie.org. Consulté le 11-05-2014.
[18]
Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial disk susceptibility tests. Wayne: CLSI document. p. M02-A12. 2015.
[19]
Gisbert JP. The recurrence of Helicobacter pylori infection: incidence and variables influencing it. A critical review. Am J Gastroenterol. 2005; 100: 2083-2099.
[20]
Megraud F. Resistance of Helicobacter pylori to antibiotics. Aliment Pharmacol Ther. 1997; 11 (suppl1): 43-53.
[21]
Soll AH. Consensus conference. Medical treatment of peptic ulcer disease. Practice guidelines. Practice Parameters Committee of the American College of Gastroenterology. JAMA. 1996; 275: 622-629.
[22]
Malfertheiner P, Bayerdorffer E, Diete U, Gil J, Lind T, Misiuna P, et al. The GU-MACH study: the effect of 1-week omeprazole triple therapy on Helicobacter pylori infection in patients with gastric ulcer. Aliment Pharmacol Ther. 1999; 13: 703-712.
[23]
Kobayashi I, Murakami K, Kato M et al. Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005. J. Clin. Microbiol. 2007; 45: 4006-4010.
[24]
Boyanova L, Gergova G, Nikolov R et al. Prevalence and evolution of Helicobacter pylori resistance to 6 antibacterial agents over 12 years and correlation between susceptibility testing methods. Diagn. Microbiol. Infect. Dis. 2008; 60: 409-415.
[25]
De Francesco V, Margiotta M, Zullo A et al. Prevalence of primary clarithromycin resistance in Helicobacter pylori strains over a 15 year period in Italy. J. Antimicrob. Chemother. 2007; 59: 783-785.
[26]
Malekzadeh R, Mohamadnejad M, Siavoshi F, Massarrat S. Treatment of Helicobacter pylori infection in Iran: low efficacy of recommended western regimens. Arch Iran Med. 2004; 7: 1-8.
[27]
Elviss NC, Owen RJ, Xerry J, Walker AM, Davies K. Helicobacter pylori antibiotic resistance patterns and genotypes in adult dyspeptic patients from a regional population in North Wales. J. Antimicrob. Chemother. 2004; 54: 435-440.
[28]
Janssen MJ, Hendrikse L, de Boer SY et al. Helicobacter pylori antibiotic resistance in a Dutch region: trends over time. Neth. J. Med. 2006; 64: 191-195.
[29]
Storskrubb T, Aro P, Ronkainen J et al. Antimicrobial susceptibility of Helicobacter pylori strains in a random adult Swedish population. Helicobacter. 2006; 11: 224-230.
[30]
Boyanova L, Mitov I. Geographic map and evolution of primary Helicobacter pylori resistance to antibacterial agents. Expert Rev Anti Infect Ther. 2010; 8: 59-70.
[31]
Kim JM, Kim JS, Jung HC, Kim N, Kim YJ, Song IS. Distribution of antibiotic MICs for Helicobacter pylori strains over a 16-year period in patients from Seoul, South Korea. Antimicrob. Agents Chemother. 2004; 48: 4843-4847.
[32]
Van de Sande-Bruinsma N, Grundmann H, Verloo D et al.; European Antimicrobial Resistance Surveillance System Group; European Surveillance of Antimicrobial Consumption Project Group. Antimicrobial drug use and resistance in Europe. Emerg. Infect. Dis. 2008; 14: 1722-1730.
[33]
ESAC Yearbook 2006. European Surveillance of Antimicrobial Consumption data www.esac.ua.ac.be/.
[34]
Glupezynski Y, Megraud F, Lopez-Brea M, Andersen LP. European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis. 2001; 20: 820-3.
[35]
Storskrubb T, Aro P, Ronkainen J, Wreiber K, Nyhlin H, Bolling-Sternevald E, et al. Antimicrobial susceptibility of Helicobacter pylori strains in a random adult Swedish population. Helicobacter. 2006; 11: 224-30.
[36]
Loivukene K, Maaroos HI, Kolk H, Kull I, Labotkin K, Mikelsaar M. Prevalence of antibiotic resistance of Helicobacter pylori isolates in Estonia during 1995-2000 in comparison to the consumption of antibiotics used in treatment regimens. Clin Microbiol Infect. 2002; 8: 598-603.
[37]
Sharara AI, Chedid M, Araj GF, Barada KA, Mourad FH. Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxicillin and tetracycline in Lebanon. Int Antimicrob Agents. 2002; 19: 155-158.
[38]
Hung K-H, Sheu B-S, Chang W-L, Wu H-M, Liu C-C, Wu J-J. Prevalence of primary fluoroquinolone resistance among clinical isolates of Helicobacter pylori at a University Hospital in Southern Taiwan. Helicobacter. 2009; 14: 61-65.
[39]
Chang WL, Sheu BS, Cheng HC, Yang YJ, Yang HB, Wu JJ. Resistance to metronidazole, clarithromycin and levofloxacin of Helicobacter pylori before and after clarithromycin-based therapy in Taiwan. J. Gastroenterol. Hepatol. 2009; 24: 1230-1235.
[40]
Chisholm SA, Teare EL, Davies K, Owen RJ. Surveillance of primary antibiotic resistance of Helicobacter pylori at centres in England and Wales over a six-year period (2000–2005). Euro Surveill. 2007; 12: E3-E4.
[41]
Pereyra LV, Gorordo Ipiña RC, Berruezo FA, Amieva CA, García ME, Bottiglieri MT. Sensibilidad a los antimicrobianos de aislamientos de Helicobacter pylori aislados de lesiones gástricas. Rev Argent Microbiol. 2017; 49: 153-157.
[42]
Otth L, Wilson M, Fernández H, Otth C, Toledo C, Cárcamo V, et al. Isolation of Helicobacter pylori in gastric mucosa and susceptibility to five antimicrobial drugs in Southern Chile. Braz J Microbiol. 2011; 42: 442-447.
[43]
González CC, García CA, Daroch MF, Kawaguchi PF, Solar RH, Rivera FN, et al. Susceptibilidad in vitro de cepas de Helicobacter pylori: aislamiento de cepas resistentes a claritromicina. Rev Méd Chile. 2001; 129: 643-646.
[44]
Lang L, Garcia F. Comparison of E-test and disk diffusion assay to evaluate resistance of Helicobacter pylori isolates to amoxicillin, clarithromycin, metronidazole and tetracycline in Costa Rica. Int J Antimicrob Agents. 2004; 24: 572-577.
[45]
Torres J, Camorlinga-Ponce M, Perez-Perez G, Madrazo-De la Garza A, Dehesa M, Gonzalez-Valencia G, et al. Increasing multidrug resistance in Helicobacter pylori strains isolated from children and adults in Mexico. J Clin Microbiol. 2001; 39: 2677-2680.
Browse journals by subject